PPP4R3A and carcinoma: In order to check the combination effects, when OVCAR-3 carcinoma cells were transfected with sMEK1 (0.6 μg) and treated with paclitaxel (20 μM), cell viability was reduced by >70%, whereas a 20–30% less reduction in cell viability resulted from transfection with sMEK1 or cells treated with paclitaxel alone (Fig. 1B, left panel).